Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × HER2-negative Breast Cancer × Carboplatin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 632 Lung Neoplasms 271 Ovarian Neoplasms 269 Breast Neoplasms 222 Fallopian Tube Neoplasms 133 Neoplasms 116 Small Cell Lung Carcinoma 113 Triple Negative Breast Neoplasms 109 Squamous Cell Carcinoma of Head and Neck 100 Carcinoma, Ovarian Epithelial 95 Neoplasm Metastasis 69 Head and Neck Neoplasms 66 Endometrial Neoplasms 63 Uterine Cervical Neoplasms 56 Adenocarcinoma of Lung 55 Esophageal Neoplasms 54 Central Nervous System Neoplasms 44 Brain Neoplasms 44 Recurrence 41 Prostatic Neoplasms 40 Lymphoma, Large B-Cell, Diffuse 38 Carcinoma 38 Parkinson Disease 4, Autosomal Dominant Lewy Body 37 Neuroblastoma 37 Urinary Bladder Neoplasms 36 Lymphoma 33 Esophageal Squamous Cell Carcinoma 32 Carcinoma, Squamous Cell 29 Melanoma 27 Colorectal Neoplasms 27

Interventions

eribulin 2 Vinorelbine 2 Paclitaxel 2 Cyclophosphamide 2 trastuzumab deruxtecan 1 taxane 1 sacituzumab govitecan 1 pembrolizumab 1 pamiparib 1 liposomal doxorubicin 1 camrelizumab 1 Precision Medicine 1 Gemcitabine 1 Epirubicin 1 Doxorubicin 1 Docetaxel 1 Cisplatin 1 Carboplatin 1 Capecitabine 1 Anthracyclines 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06102824 2024-11-25

ORIENTA

Guangdong Provincial People's Hospital

Phase 2 Recruiting

HER2-negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡